Lucid Group Appoints Former Pfizer R&D Leader Rod MacKenzie, CMG, PhD, as Board Chair to Drive Next Phase of Global Growth and Innovation
March 18, 2026 |
Appointment marks a pivotal step in Lucid’s next phase of growth, strengthening its ability to translate complex science into real-world impact.
Lucid’s US Medical Affairs division unveils new proprietary insights tools to expand advisory capabilities.
LONDON & PHILADELPHIA, March 18, 2026 – Lucid Group, a global leader in healthcare communications and commercialisation, today announced that Rod MacKenzie, CMG, PhD, former Executive Vice President and Chief Development Officer at Pfizer, has been appointed as the new Chair of the Lucid Group Board of Directors. Dr MacKenzie will succeed Andy Black, who retired from the Board following the end of his term.
This appointment reflects a shared mission with Lucid Group to transform lives by ensuring innovative medicine doesn’t stop at approval but reaches the patients who need it most. His leadership marks a pivotal step in Lucid’s next phase of growth, strengthening its ability to translate complex science into real-world impact.
“Dr MacKenzie’s career is defined by his dedication to patient outcomes and a deep understanding that breakthrough science only matters when translated into action,” said Rick Sannem, CEO of Lucid Group. “His arrival supports our shared vision that we don’t just help clients talk about their science, we uncover the defining insights that shape behaviour so life-changing medicines find their rightful place in the market.”
Dr MacKenzie spent 34 years at Pfizer, where he led the Global Product Development division and oversaw 6,000 professionals dedicated to advancing innovative medicines and vaccines. He played a critical role in the development of both the Pfizer-BioNTech COVID-19 vaccine and antiviral, Paxlovid, in addition to serving on Pfizer’s Executive Leadership Team from 2016 to 2022. In recognition of his contributions to public health during the pandemic, he was appointed Companion of the Order of St Michael and St George by Queen Elizabeth II in 2022.
“Inventing and developing innovative medicines takes great science and execution. But translating that science into improved patient outcomes in clinical practice requires real strategic discipline,” said Dr MacKenzie. “Even brilliant science can struggle to break through, so innovative companies need a strategic partner like Lucid, whose integrated approach to solving complex challenges delivers changes in behaviours that successfully overcome treatment barriers. Lucid’s cre
ativity and unique data synthesis capabilities really stand out in the marketplace. I am thrilled to join the Lucid Board and share Lucid’s deep commitment to transforming lives across the globe.”
In addition to Dr MacKenzie’s appointment, Lucid’s US Medical Affairs division is unveiling new proprietary insights tools to expand its advisory capabilities at the Medical Affairs Professional Society (MAPS) conference in Denver from 22-25 March:
- Influence Amplifier™ – Closes the gap between communication and behaviour change by combining real-time behavioural insights, precision targeting, and adaptive analytics to expand peer-to-peer communication relevance and audience priorities.
- Impact Validator™ – Pinpoints precisely where efforts drive change through a five-step framework spanning clinical gaps and audience priorities, tailored interventions, omnichannel engagement, performance data, and adaptive refinement.
Together, these tools magnify and document scientific impact while delivering Precision Engagement™, a repeatable, self‑optimising cycle that continuously strengthens scientific influence, impact, and patient outcomes over time.
To demonstrate how Lucid Medical is enabling Medical Affairs teams to be strategic catalysts for change, it is offering free, 30-minute Impact Calibration™ sessions designed to map Medical Affairs teams’ current influence and spotlight opportunities for measurable growth.
About Lucid Group
Lucid Group, a global leader in healthcare communications and commercialisation, is driven by a mission to transform lives by bridging the gap between scientific discovery and patient impact. For life sciences organisations navigating their highest-stakes decisions, Lucid doesn’t just communicate science but ensures clients leave a lasting impact on the market and the patients they serve. Lucid brings together experts across Strategy Consulting, Scientific and Medical Communications, and Commercial Communications, fusing scientific rigour, strategic foresight, commercial ingenuity, creative storytelling, and deep human insight into an integrated force, powered by real-world evidence. This unique approach allows Lucid to uncover the ‘Lucid Truth’— the deep-seated insight that governs stakeholder behaviour and anchors bold, behaviour-changing ideas, executed at key moments and accelerated by AI and technology. To learn more about Lucid Group, visit www.wearelucidgroup.com and LinkedIn.
Media Contacts:
Chris Dougherty
CDougherty@reboundb2b.com
Elyse Cole
media@wearelucidgroup.com
This content was provided by Lucid Group Communications Limited
Company Details
Latest Content from Lucid Group Communications Limited
Lucid Group shine the spotlight on mental and physical health
Lucid kick-started its health and wellbeing agenda for the year with a focus on physical and mental wellbeing by taking inspiration from an elite sportsman, James Rodwell. James, a decorated...
It’s Teenage Kicks for Lucid Group
Lucid has been celebrating its 13th birthday this week. From New York to Singapore, Dubai, Macclesfield and London, teams have been gathering to celebrate the start of its teenage years.The...
Lighthouse Medical Communications US – An opportunity of a lifetime to be part of the Lucid Group magic
Our family at Lighthouse Medical Communications US are looking for talented individuals to join its team in hashtagManhattan. If you want to be part of something magical get in touch...
Lucid Learning and Development
Julieann Tate, Head of hashtagLearning and Development at Lucid Group, discusses the new programmes and tools she has been busy developing and rolling out throughout the organisation — Elevating employee...
Lucid Learning and Development
Julianne Tate, Head of Learning and Development at Lucid Group, discusses the new programmes and tools that she has been busy developing and rolling out throughout the Group — Elevating...
Lucid Group Announce Neil Flash as its New Chief Commercial Officer
With over 20 years’ healthcare communications experience, Neil Flash joins Lucid Group as its Chief Commercial Officer to help lead the organisation through another exciting period of growth.
My Journey into Medical Communications #LucidLife
In NetworkPharma's latest career guide for wannabe account managers, our very own Aveen Hamid discusses her journey into medical communications and the opportunity to work on programmes that transform patients’...
Lucid Group adds more magic to the mix with four new hires
Leading Edge, a Lucid Group company, injects new talent into its client services and medical writing teams. Miranda Harrison joins the team as its Client Operations Director. Miranda is a...
Lucid Group expands its presence in the north-west with six new hires
Healthcare 21, a Lucid Group company, continues to strengthen its editorial and medical writing team with six new additions to its Macclesfield office.Rosanna Farrell joins HealthCare 21 as a Senior...
There’s lots to celebrate as Lighthouse marks its five year anniversary
Based in Manhattan, Lighthouse Medical Communications US has grown significantly over the last five years, both in terms of team and client roster. Lisa Druce, Managing Partner comments, “Every year,...